Clofarabine

Clofarabine

File:Clofarabine.svg
Clinical data
ATC code	L01BB06 (WHO)
Identifiers
IUPAC name 5-(6-amino-2-chloro-purin-9-yl) -4-fluoro-2- (hydroxymethyl)oxolan-3-ol
CAS Number	123318-82-1
PubChem CID	119182
DrugBank	APRD00878
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10HClFN5O3
Molar mass	303.677 g/mol

WikiDoc Resources for Clofarabine
Articles
Most recent articles on Clofarabine Most cited articles on Clofarabine Review articles on Clofarabine Articles on Clofarabine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Clofarabine Images of Clofarabine Photos of Clofarabine Podcasts & MP3s on Clofarabine Videos on Clofarabine
Evidence Based Medicine
Cochrane Collaboration on Clofarabine Bandolier on Clofarabine TRIP on Clofarabine
Clinical Trials
Ongoing Trials on Clofarabine at Clinical Trials.gov Trial results on Clofarabine Clinical Trials on Clofarabine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Clofarabine NICE Guidance on Clofarabine NHS PRODIGY Guidance FDA on Clofarabine CDC on Clofarabine
Books
Books on Clofarabine
News
Clofarabine in the news Be alerted to news on Clofarabine News trends on Clofarabine
Commentary
Blogs on Clofarabine
Definitions
Definitions of Clofarabine
Patient Resources / Community
Patient resources on Clofarabine Discussion groups on Clofarabine Patient Handouts on Clofarabine Directions to Hospitals Treating Clofarabine Risk calculators and risk factors for Clofarabine
Healthcare Provider Resources
Symptoms of Clofarabine Causes & Risk Factors for Clofarabine Diagnostic studies for Clofarabine Treatment of Clofarabine
Continuing Medical Education (CME)
CME Programs on Clofarabine
International
Clofarabine en Espanol Clofarabine en Francais
Business
Clofarabine in the Marketplace Patents on Clofarabine
Experimental / Informatics
List of terms related to Clofarabine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Clofarabine is a substance that is being studied in the treatment of cancer. It is a purine nucleoside antimetabolite. It is marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra.

It is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if extends life expectancy. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out.

Side effects

• Tumor lysis syndrome (TLS). Clofarabine quickly kills leukaemia cells in the blood. The body may react to this. Symptoms include fast breathing, fast heartbeat, low blood pressure, and fluid in the lungs. TLS is very serious and can lead to death if it is not treated right away.
• Bone marrow problems (suppression). Clofarabine can stop the bone marrow from making enough red blood cells, white blood cells, and platelets. Serious side effects that can happen because of bone marrow suppression include severe infection (sepsis), bleeding, and anemia.
• Effects on pregnancy and breastfeeding. Girls and women should not become pregnant or breastfeed during treatment which harm the baby.
• Dehydration and low blood pressure. Clofarabine can cause vomiting and diarrhea which may lead to low body fluid (dehydration). Signs and symptoms of dehydration include dizziness, lightheadedness, fainting spells, or decreased urination.
• Other side effects. The most common side effects are stomach problems (including vomiting, diarrhea, and nausea), and effects on blood cells (including low red blood cells count, low white blood cell count, low platelet count, fever, and infection. Clofarabine can also cause tachycardia and can affect the liver and kidneys.

Contraindications

• pregnancy or planned pregnancy
• breast-feeding
• liver problems
• kidney problems

Drug interactions

• nephrotoxic drugs
• hepatotoxic drugs

Delivery

• By intravenous infusion.
• Dosage is a 2 hour infusion (52 mg/m²) every day for five days. The cycle is repeated every 2 to 6 weeks.
• Regular blood tests to monitor his or her blood cells, kidney function, and liver function.

Results of clinical trials

Efficacy and safety were demonstrated in a single multi-center trial that enrolled 40 patients aged 2-19. The patients were suffering with relapsed or refractory acute lymphoblastic leukaemia (ALL) (An additional 9 patients suffering with acute myelogenous leukaemia (AML) had similar pharmacokinetics but are not included in the figure below.) Most patients had received 2 to 4 prior regimens and 15/49 (31%) had undergone at least one transplant. The median age was 12 years. Clofarabine was given at a dose of 52 mg/m², intravenously, over 2 hours daily x 5 repeated every 2 to 6 weeks following recovery or return to baseline organ function. The study endpoints were the rate of complete response (CR) and the rate of complete response without platelet recovery (CRp). The former was defined as no evidence of circulating blasts or extramedullary disease, an M1 bone marrow, and recovery of peripheral platelet and absolute neutrophil counts; the latter was defined as meeting all criteria for CR except for platelet count recovery. Response rates were determined by an Independent Response Review Panel (IRRP).

Six patients (12%) achieved a CR and 4 patients (8%) achieved a CRp, and 5 patients (10%) achieved a PR. Of the 15 responding patients, 6 had post-clofarabine bone marrow transplantation. Hence, response durations could not be determined. In the patients who were not transplanted, the response durations for CR were 43, 50, 82, 93+, and 160+ days; for CRp the response duration was 32 days.

The principal clofarabine toxicities were nausea, vomiting, hematologic toxicity, febrile neutropenia, hepatobiliary toxicity, infections and renal toxicity. Clofarabine can produce systemic inflammatory response syndrome/capillary leak syndrome (SIRS), manifested by the rapid development of tachypnea, tachycardia, hypotension, shock, and multi-organ failure. Cardiac toxicity was characterized as left ventricular systolic dysfunction; tachycardia may also occur.

Approval

Clolar Food and Drug Administration (FDA) Approved 28 december 2004. (Under accelerated approval regulations requiring further clinical studies.)

Patents

• U.S. Patent 4,751,221
• U.S. Patent 4,918,179
• U.S. Patent 5,384,310
• U.S. Patent 5,661,136
• U.S. Patent 6,680,382

External links

• Clofarabine information on Cancerbackup.
• FDA usage leaflet.
• Clolar.com homepage.
• FDA approval notice.